DJ Sartorius Stedim Biotech SA: Information on Document Availability
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability
19-Jul-2024 / 09:50 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Aubagne, July 19, 2024
Information on Document Availability
The report on the first half 2024 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations
It contains the following information:
- Business development for the period of January to June 2024 as well as the 2024 full year forecast for
the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2024
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider
of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture
biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of
Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach
with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius
Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In
2023, the company generated sales revenue of around 2.8 billion euros. By the end of 2023, more than
10,600 employees were working for customers around the globe.
Contact
Petra Müller
Head of Investor Relations
+49 (0)551.308.6035
petra.mueller2@sartorius.com
=----------------------------------------------------------------------------------------------------------------------
Regulatory filing PDF file
File: 2024_SSB_Document availability H1_en
=----------------------------------------------------------------------------------------------------------------------
Language: English
Company: Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone: +33 44 284 5600
E-mail: sartorius.presse@sartorius.com
Internet: www.sartorius-stedim.com
ISIN: FR0013154002
Euronext DIM
Ticker:
AMF Category: Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly
financial report
EQS News ID: 1950133
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
1950133 19-Jul-2024 CET/CEST
Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1950133&application_name=news&site_id=dow_jones%7e%7e%7ef1066a31-ca00-4e1a-b0a4-374bd7d0face
(END) Dow Jones Newswires
July 19, 2024 03:50 ET (07:50 GMT)
© 2024 Dow Jones News
